Mutation detection with Quantitative Real Time PCR (Q-PCR)

Boehringer Ingelheim

Quantitative real-time polymerase chain reaction, or Q-PCR, is a valuable tool for detecting specific gene sequences within a patient’s tumor sample, including mutations in key oncogenes.1,2

The expanded use of technologies such as Q-PCR, at both local and centralized laboratories, can be instrumental in the implementation of personalized medicine strategies.4,5

References

1. Newton CR, Graham A, Heptinstall LE, et al. Nucleic Acids Res. 1989;17(7):2503-2516.

2. Whitcombe D, Theaker J, Guy SP, Brown T, Little S. Nat Biotechnol. 1999;17(8):804-807.

3. Horiike A, Kimura H, Nishio K, et al. Chest. 2007;131(6):1628-1634.

4. Li AR, Chitale D, Riely GJ, et al. J Mol Diagn. 2008;10(3):242-248.

5. Mok TS, Wu YL, Thongprasert S, et al. N Engl J Med. 2009;361(10):947-957.

Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.

† Not an official event of the 2012 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Boehringer Ingelheim on